Vasopressin in chronic kidney disease: an elephant in the room? | Zendy

Vicente E. Torres | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Vasopressin in chronic kidney disease: an elephant in the room?

Author(s) -

Vicente E. Torres

Publication year - 2009

Publication title -

kidney international

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.499

H-Index - 276

eISSN - 1523-1755

pISSN - 0085-2538

DOI - 10.1038/ki.2009.325

Subject(s) - vasopressin , medicine , endocrinology , glomerulosclerosis , vasopressin receptor , kidney disease , kidney , angiotensin ii , blood pressure , arginine vasopressin receptor 2 , nephrectomy , proteinuria , receptor , antagonist

Perico et al. report that a dual arginine vasopressin (AVP) V(2) and V(1a) receptor antagonist lowers blood pressure, proteinuria, and glomerulosclerosis in 5/6 nephrectomized rats, pointing to its potential value in the treatment of chronic kidney disease (CKD). AVP likely contributes to CKD progression by its effects on renal hemodynamics, blood pressure, and mesangial and/or epithelial cells, but the relative contributions of V(2) and V(1a) receptors and potential usefulness of V(2) and V(1a) receptor antagonists remain ill defined.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research